You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

TAMK (TAM kinase)

Showing 1 - 25 of 2,066
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Tumor Metastasis Trial in Worldwide (PF-07265807, Sasanlimab, Axitinib)

Recruiting
  • Neoplasm Metastasis
  • Fayetteville, Arkansas
  • +33 more
Aug 20, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Australia, Poland (TG-1701, Umbralisib, Ublituximab)

Active, not recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • East Melbourne, Victoria, Australia
  • +7 more
Jan 20, 2023

Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian

Not yet recruiting
  • Hormone-receptor-positive Breast Cancer
  • +3 more
  • Aromatase inhibitor
  • +3 more
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Apr 5, 2023

Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest Trial in New Hyde Park (Medtronic

Recruiting
  • Atrial Fibrillation
  • +4 more
  • Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
  • New Hyde Park, New York
    Northwell (Northshore University/Long Island Jewish Hospitals)
Dec 1, 2022

Atypical Hyperplasia, Lobular Carcinoma in Situ Trial in Rochester (Tamoxifen, Topical 4-OHT( 4-hydroxytamoxifen)gel 2 mg/each

Recruiting
  • Atypical Hyperplasia
  • Lobular Carcinoma in Situ
  • Evanston, Illinois
  • +1 more
Jan 20, 2023

"Don't Eat me" Signal in Hematological Malignancies: CD24 as New

Recruiting
  • Mantle-cell Lymphoma
  • B Cell Chronic Lymphocytic Leukemia
    • Monza, MB, Italy
      Andrea Aroldi
    May 24, 2023

    MammaPrint Value for Pre-menopausal Breast Cancer Patients

    Recruiting
    • Breast Cancer
      • Shanghai, Shanghai, China
        Fudan University Shanghai Cancer Center
      Jul 25, 2022

      Duchenne Muscular Dystrophy Trial in Worldwide (Tamoxifen, Matching )

      Completed
      • Duchenne Muscular Dystrophy
      • Garches, France
      • +10 more
      Dec 19, 2022

      Chronic Lymphocytic Leukemia, CLL, SLL Trial in United States (TP-0903, TP-0903 and ibrutinib combination therapy)

      Terminated
      Has Results
      • Chronic Lymphocytic Leukemia
      • +3 more
      • TP-0903
      • TP-0903 and ibrutinib combination therapy
      • Phoenix, Arizona
      • +5 more
      Apr 4, 2022

      Educational Problems Trial in Fujisawa (3D printing technology learning program)

      Recruiting
      • Educational Problems
      • 3D printing technology learning program
      • Fujisawa, Kanayama, Japan
        shonan keiiku Hospital
      Jan 12, 2023

      Melasma Trial in Karachi (TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C), Kligman formula (hydroquinone 4%,

      Active, not recruiting
      • Melasma
      • TAM formula (hydroquinone 2%, tretinoin 0.05% and 5% vitamin C)
      • Kligman formula (hydroquinone 4%, fluocinolone acetonide 0.01% and tretinoin 0.05%)
      • Karachi, Sindh, Pakistan
        JPMC
      Aug 25, 2023

      Biological Characteristics of Mesothelioma Patients

      Completed
      • Malignant Mesothelioma
        • Rozzano, Milano, Italy
        • +1 more
        Sep 8, 2022

        Cancer of the Colon Trial in Marseille (BLOOD AND TUMOR)

        Recruiting
        • Cancer of the Colon
        • BLOOD AND TUMOR
        • Marseille, France
          Institut Paoli Calmettes
        Jul 12, 2023

        Neutrophil Extracellular Traps Formation in Breast Cancer

        Recruiting
        • Breast Carcinoma
        • Biospecimen Collection
        • Electronic Health Record Review
        • Houston, Texas
          M D Anderson Cancer Center
        Sep 27, 2022

        Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

        Active, not recruiting
        • Neurofibromatosis 1
        • Neurofibroma Plexiform
        • Shanghai, China
        • +1 more
        Jan 13, 2023

        COVID-19 Trial in Chengdu (VV116+SOC, SOC)

        Recruiting
        • COVID-19
        • Chengdu, Sichuan, China
          Chengdu Zenitar Biomedical Technology Co., Ltd
        Feb 3, 2023

        Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Trial in Worldwide (procedure, other, drug)

        Recruiting
        • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
        • Biospecimen Collection
        • +4 more
        • Birmingham, Alabama
        • +170 more
        Jan 30, 2023

        Burns, Hand Burn, Hand Grasp Trial in Al ?ayy Ath Thamin (device, behavioral, procedure, other)

        Active, not recruiting
        • Burns
        • +3 more
        • Light emitting diode therapy (LED therapy)
        • +3 more
        • Al Ḩayy Ath Thāmin, Giza, Egypt
          October 6 University Hospital
        May 6, 2022

        Lung Cancer, Non Small Cell Lung Cancer Trial in Aurora (Amivantamab 1050mg, Amivantamab 1400mg, Amivantamab (to be determined))

        Not yet recruiting
        • Lung Cancer
        • Non Small Cell Lung Cancer
        • Amivantamab 1050mg
        • +2 more
        • Aurora, Colorado
        • +2 more
        Apr 25, 2023

        Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

        Recruiting
        • Locally Advanced Solid Tumors
        • +3 more
        • Oral repotrectinib (TPX-0005)
        • Los Angeles, California
        • +27 more
        Aug 9, 2022

        Pancreatic Ductal Adenocarcinoma Trial (combination therapy with no MEKi, combination therapy with MEKi-HCQ, combination therapy

        Not yet recruiting
        • Pancreatic Ductal Adenocarcinoma
        • combination therapy with no MEKi
        • +3 more
        • (no location specified)
        Nov 29, 2022

        Advanced or Metastatic Solid Tumors Trial in San Antonio (RXDX-106)

        Terminated
        • Advanced or Metastatic Solid Tumors
        • San Antonio, Texas
          START
        Apr 24, 2019

        Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

        Not yet recruiting
        • Liver Transplant; Complications
        • +3 more
        • multi-kinase inhibitors in combination with bevacizumab
        • Beijing, Beijing, China
          Chinese Academy of Medical Sciences & Peking Union Medical Colle
        Sep 11, 2023

        The Antiaggregation Monitoring (TAM) Registry

        Completed
        • Aspirin Causing Adverse Effects in Therapeutic Use
        • Measurement of platelet anti-aggregation
        • Fribourg, FR, Switzerland
          Service de Cardiologie, Hôpital Cantonal Fribourg
        Oct 14, 2021

        Cancer Trial in Changsha (Protein Kinase Inhibitor)

        Recruiting
        • Cancer
        • Protein Kinase Inhibitor
        • Changsha, Hunan, China
          Central South University
        Jun 23, 2022